Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SPERO THERAPEUTICS, INC.

(SPRO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
11.6(c) 11.67(c) 11.62(c) 11.5(c) 11.4(c) Last
176 409 221 196 130 634 122 263 182 072 Volume
-3.73% +0.60% -0.43% -1.03% -0.87% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 20,4 M - -
Net income 2021 -84,0 M - -
Net cash position 2021 140 M - -
P/E ratio 2021 -4,18x
Yield 2021 -
Sales 2022 22,0 M - -
Net income 2022 -115 M - -
Net cash position 2022 113 M - -
P/E ratio 2022 -3,41x
Yield 2022 -
Capitalization 368 M 368 M -
EV / Sales 2021 11,2x
EV / Sales 2022 11,6x
Nbr of Employees 89
Free-Float 83,7%
More Financials
Company
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). It is also developing... 
More about the company
Ratings of Spero Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about SPERO THERAPEUTICS, INC.
01/25SPERO THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements an..
AQ
01/19Spero Therapeutics Receives Additional $12.9 Million in BARDA Funding for Tebipenem to ..
MT
01/19SPERO THERAPEUTICS : Awarded up to an Additional $12.9 Million by BARDA to Support the Dev..
PU
01/19SPERO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/19Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the De..
AQ
01/19Spero Therapeutics Receives Up to an Additional $12.9 Million by BARDA to Support the D..
CI
01/04Health Care Stocks Stumble Through Weak Tuesday Session
MT
01/04Health Care Stocks Retreating Tuesday as Biotechs Sink
MT
01/04Spero Therapeutics Says FDA Lifted Clinical Hold on Phase 2 Trial of SPR720; Shares Cli..
MT
01/04Spero Therapeutics Says FDA Lifts Clinical Hold on SPR720 Phase 2 Trial
DJ
01/04SPERO THERAPEUTICS : Announces FDA Acceptance and Priority Review of New Drug Application ..
PU
01/04SPERO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/04Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720
AQ
01/04Spero Therapeutics, Inc. Announces Lifting of FDA Clinical Trial Hold on SPR720
CI
01/03INSIDER BUY : Spero Therapeutics
MT
More news
News in other languages on SPERO THERAPEUTICS, INC.
01/04Les actions du secteur de la santé trébuchent lors de la faible séance de mardi
01/04Les actions du secteur de la santé reculent mardi alors que les biotechnologies chutent
01/04Spero Therapeutics déclare que la FDA a levé le blocage clinique de l'essai de phase 2 ..
01/04Spero Therapeutics, Inc. annonce la levée de la suspension des essais cliniques du SPR7..
01/03ACHATS D'INITIÉS : Spero Therapeutics
More news
Analyst Recommendations on SPERO THERAPEUTICS, INC.
More recommendations
Chart SPERO THERAPEUTICS, INC.
Duration : Period :
Spero Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPERO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 11,40 $
Average target price 41,20 $
Spread / Average Target 261%
EPS Revisions
Managers and Directors
Ankit A. Mahadevia President, Chief Executive Officer & Director
Satyavrat Shukla Treasurer, Chief Financial & Accounting Officer
Milind S. Deshpande Chairman
Thomas R. Parr Chief Scientific Officer
David Melnick Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SPERO THERAPEUTICS, INC.-28.79%368
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-12.95%47 040
BIONTECH SE-40.05%37 325